SUNLIGHT trial meets primary endpoint in refractory metastatic CRC - Medical Conferences
Overall survival according to continuation or discontinuation of... | Download Scientific Diagram
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial | Journal of Clinical Oncology
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Oncology
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial - ScienceDirect
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial - ScienceDirect
Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study - Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne ...
Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial | International
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Scientific Reports
![PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1f2882819a61e3853acfa2fdb64e9ae4bb6b3252/5-Figure2-1.png "PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar")
PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar
Promising Treatments Boost Positive Extended Results in HCC - U.S. Medicine
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
Progression-free survival and overall survival of patients treated with... | Download Scientific Diagram
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | Journal of Neuro-Oncology
Overall survival and progression-free survival by hyper | Open-i
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study - ScienceDirect
Avastin® (bevacizumab) Clinical Trials | CC Treatment
News Articles | ESMO
Figure 2 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) | Journal of Clinical Oncology
